Jenkins V, Farewell V, May S, Catt S, Matthews L, Shilling V, Dickson J, Simcock R, Fallowfield L. Do drugs offering only PFS maintain quality of life sufficiently from a patient's perspective? Results from AVALPROFS (Assessing the 'VALue' to patients of PROgression Free Survival) study. Support Care Cancer. 2018 May 29. doi: 10.1007/s00520-018-4273-3. [Epub ahead of print]
Catt SL, Ahmad S, Collyer J, Hardwick L, Shah N, Winchester L. Quality of life and communication in orthognathic treatment. J Orthod. 2018 Jun;45(2):65-70.
Catt S, Sheward J, Sheward E, Harder H. Cancer survivors' experiences of a community-based cancer-specific exercise programme: results of an exploratory survey. Support Care Cancer. 2018 Apr 5. doi: 10.1007/s00520-018-4179-0. [Epub ahead of print]
Jenkins V, Payne H, Mason M, May S, Matthews L, Catt S. EXTREQOL Identifies Ongoing Challenges in Maximising Quality of Survival in Men with Metastatic Castrate-resistant Prostate Cancer. Clin Oncol (R Coll Radiol). 2018 Jun;30(6):331-333.
Catt S, Starkings R, Shilling V, Fallowfield L. Patient-reported outcome measures of the impact of cancer on patients' everyday lives: a systematic review. J Cancer Surviv. 2017 Apr;11(2):211-232.
Fallowfield LJ, Catt SL, May SF, Matthews L, Shilling VM, Simcock R, Westwell S, Jenkins VA. Therapeutic aims of drugs offering only progression-free survival are misunderstood by patients, and oncologists may be overly optimistic about likely benefits. Support Care Cancer. 2017 Jan;25(1):237-244.
Nikapota A, Cresswell J, Appleyard S, Catt S. Quality of Life after Bladder Cancer: A Prospective Study Comparing Patient-related Outcomes after Radical Surgery or Radical Radiotherapy for Bladder Cancer. Clinical Oncology. 2015;.
Jenkins V, Catt S, Banerjee S, Gourley C, Montes A, Solis-Trapala I et al. Patients’ and oncologists’ views on the treatment and care of advanced ovarian cancer in the UK: results from the ADVOCATE study. Br J Cancer. 2013;108(11):2264-2271.
Fallowfield L, Francis A, Catt S, Mackenzie M, Jenkins V. Time for a low-risk DCIS trial: harnessing public and patient involvement. The Lancet Oncology. 2012;13(12):1183-1185.
Catt S, Chalmers A, Critchley G, Fallowfield L. Supportive follow-up in patients treated with radical intent for high-grade glioma. CNS Oncology. 2012;1(1):39-48.